TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 30561744

Group type: EXPERIMENTAL
Intervention: Contralateral prophylactic mastectomy (CPM) discussions initiated by patients or providers
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Patient interest in pursuing CPM
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Provider responses to CPM discussions
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Agreement levels on CPM discussions
Number of subjects: 36
Study: 30903614

Group type: EXPERIMENTAL
Intervention: Dental pain
Number of subjects: 306

Group type: EXPERIMENTAL
Intervention: Monthly household income
Number of subjects: 306

Group type: EXPERIMENTAL
Intervention: Dental caries
Number of subjects: 306
Study: 30122579

Group type: EXPERIMENTAL
Intervention: Dinoprostone vaginal tablets
Number of subjects: 0

Group type: COMPARATOR
Intervention: Dinoprostone slow release retrievable vaginal insert
Number of subjects: 0
Study: 27430304

Group type: EXPERIMENTAL
Intervention: Progressive resistance training (PRT) combined with anodal transcranial direct current stimulation (a‐tDCS) at 2 mA for 20 minutes, three times per week for 6 weeks
Number of subjects: 42

Group type: COMPARATOR
Intervention: Sham tDCS with PRT
Number of subjects: 42
Study: 25037012

Group type: EXPERIMENTAL
Intervention: Topical anesthesia
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Subconjunctival anesthesia
Number of subjects: 57
Study: 22057947

Group type: EXPERIMENTAL
Intervention: Treatment A (600 IU eCG on Day 4 after CIDR insertion)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Treatment B (300 IU eCG at the same time)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Treatment C (250 IU FSH on Day 4 post-insertion)
Number of subjects: 6
Study: 19155993

Group type: EXPERIMENTAL
Intervention: Aciclovir 400 mg twice daily for 3 months
Number of subjects: 300

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 300
Study: 17228046

Group type: EXPERIMENTAL
Intervention: Low-carbohydrate ketogenic diet (LCKD)
Number of subjects: 119

Group type: COMPARATOR
Intervention: Low-fat diet (LFD)
Number of subjects: 119
Study: 15744902

Group type: EXPERIMENTAL
Intervention: Panax notoginseng (PNG) 1,350 mg per day for 30 days
Number of subjects: 29

Group type: COMPARATOR
Intervention: Starch capsule (control) 1,350 mg per day for 30 days
Number of subjects: 29
Study: 11991217

Group type: EXPERIMENTAL
Intervention: valsartan 160 mg/day
Number of subjects: 12

Group type: COMPARATOR
Intervention: captopril 100 mg/day
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: combined therapy (valsartan + captopril)
Number of subjects: 12
Study: 9932952

Group type: EXPERIMENTAL
Intervention: MRI demonstrated loss of gray-white matter differentiation and decreased T1- and increased T2-weighted signal in the ipsilateral anterior temporal lobe (AT) in 58% of patients.
Number of subjects: 50

Group type: COMPARATOR
Intervention: Histologic quantitation showed increased glial cell nuclei counts in intractable TLE cases compared with controls.
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Presence or absence of MRI changes was not predictive of preoperative neuropsychology, postoperative change in neuropsychology, or seizure outcome after surgery.
Number of subjects: 50
Study: 7539853

Group type: EXPERIMENTAL
Intervention: Doxazosin (8 mg once daily)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Doxazosin
Number of subjects: 100
Study: 2181787

Group type: EXPERIMENTAL
Intervention: Telenzepine (3 mg in the morning)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Domperidone (10 mg t.d.s.)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Telenzepine and Domperidone
Number of subjects: 0
Study: 339141

Group type: EXPERIMENTAL
Intervention: 600 mg water-soluble bioflavonoids and 600 mg ascorbic acid, administered three times daily
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: 1000 mg water-soluble bioflavonoids and 1000 mg ascorbic acid, administered five times daily
Number of subjects: 50

Group type: COMPARATOR
Intervention: Lactose placebo
Number of subjects: 50
Study: 31707972

Group type: EXPERIMENTAL
Intervention: Experimental group (n=26)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control group (n=24)
Number of subjects: 50
Study: 30601059

Group type: EXPERIMENTAL
Intervention: Positive Strategies To Enhance Problem‐solving Skills (Positive STEPS) intervention, which includes five individual counseling sessions and daily text message reminders.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard of care control group.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Positive STEPS intervention
Number of subjects: 0
Study: 29267547

Group type: EXPERIMENTAL
Intervention: Group education strategy
Number of subjects: 238

Group type: EXPERIMENTAL
Intervention: Home visit strategy
Number of subjects: 238

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 238
Study: 26370286

Group type: EXPERIMENTAL
Intervention: Percutaneous access using Prostar(™) and Proglide(™) devices
Number of subjects: 0

Group type: COMPARATOR
Intervention: Surgical cutdown
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Preoperative nose cultures and perineal cultures
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: VAS-scores (Visual analog scale) for patient comfort
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Punch biopsies of the groin
Number of subjects: 0
Study: 23791498

Group type: EXPERIMENTAL
Intervention: Algorithmic approach of strategies to reverse cerebral desaturation
Number of subjects: 48

Group type: COMPARATOR
Intervention: No attempts to reverse cerebral desaturation (Control)
Number of subjects: 48
Study: 21461953

Group type: EXPERIMENTAL
Intervention: Health Utilities Index 3 (HUI3)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: SF‐6D derived from SF‐36
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Estimated Quality of Well‐Being (eQWB)
Number of subjects: 0
Study: 19769016

Group type: EXPERIMENTAL
Intervention: Contemplative/preparation group
Number of subjects: 159
Study: 17551855

Group type: EXPERIMENTAL
Intervention: Educational counseling (4 sessions of 1.5 hours each)
Number of subjects: 269

Group type: COMPARATOR
Intervention: Traditional support (4 sessions of 1.5 hours each)
Number of subjects: 269

Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 269
Study: 15332021

Group type: EXPERIMENTAL
Intervention: Through-the-scope balloon
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Over-the-wire balloon
Number of subjects: 30
Study: 11498062

Group type: EXPERIMENTAL
Intervention: 0.12% zinc sulfate nasal spray administered as two inhalations in each nostril four times a day
Number of subjects: 160

Group type: COMPARATOR
Intervention: Isotonic placebo spray
Number of subjects: 160
Study: 10052660

Group type: EXPERIMENTAL
Intervention: Eccentric Training Group (ETG)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Concentric Training Group (CTG)
Number of subjects: 10
Study: 1434088

Group type: EXPERIMENTAL
Intervention: 99mTc‐Teboroxime SPECT imaging
Number of subjects: 73
Study: 4016543

Group type: EXPERIMENTAL
Intervention: Augmentin (1.2g intravenously pre-operatively, with 8 additional doses for gangrenous or perforated appendices)
Number of subjects: 250

Group type: COMPARATOR
Intervention: Metronidazole (500 mg intravenously pre-operatively, with 8 additional doses for gangrenous or perforated appendices)
Number of subjects: 250

Group type: EXPERIMENTAL
Intervention: Augmentin (for gangrenous appendices)
Number of subjects: 250

Group type: COMPARATOR
Intervention: Metronidazole (for gangrenous appendices)
Number of subjects: 250

Group type: EXPERIMENTAL
Intervention: Augmentin (for perforated appendices)
Number of subjects: 250

Group type: COMPARATOR
Intervention: Metronidazole (for perforated appendices)
Number of subjects: 250
Study: 31263017

Group type: EXPERIMENTAL
Intervention: Feedback with action implementation toolbox
Number of subjects: 253530

Group type: COMPARATOR
Intervention: Feedback-only
Number of subjects: 253530
Study: 30507899

Group type: EXPERIMENTAL
Intervention: Robot-assisted gait training (RAGT)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Conventional physical therapy (CPT)
Number of subjects: 36
Study: 26385256

Group type: EXPERIMENTAL
Intervention: Mindfulness-Based Cognitive Therapy (MBCT) for 8 weeks
Number of subjects: 75

Group type: COMPARATOR
Intervention: Waitlist control group
Number of subjects: 75
Study: 25404569

Group type: EXPERIMENTAL
Intervention: Aclidinium/formoterol 400/12 μg
Number of subjects: 1925

Group type: EXPERIMENTAL
Intervention: Aclidinium/formoterol 400/6 μg
Number of subjects: 1925
Study: 23091141

Group type: EXPERIMENTAL
Intervention: Dietary supplementation of 2.5 g/kg LFA
Number of subjects: 624

Group type: EXPERIMENTAL
Intervention: Dietary supplementation of 5.0 g/kg LFA
Number of subjects: 624

Group type: COMPARATOR
Intervention: Control diet (adequate in energy and nutrients)
Number of subjects: 624
Study: 19383732

Group type: EXPERIMENTAL
Intervention: Higher haemoglobin (Hb) levels
Number of subjects: 5010

Group type: EXPERIMENTAL
Intervention: Anaemia incidence after 1 year of follow-up
Number of subjects: 5010

Group type: EXPERIMENTAL
Intervention: Change in Hb (per SD) at 12 months
Number of subjects: 5010

Group type: EXPERIMENTAL
Intervention: Anaemia at baseline
Number of subjects: 5010

Group type: EXPERIMENTAL
Intervention: Anaemia at any time during follow-up
Number of subjects: 5010
Study: 17886195

Group type: EXPERIMENTAL
Intervention: Patient education (4 x 1.5 hours) and an individual action plan
Number of subjects: 184

Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 184

Group type: EXPERIMENTAL
Intervention: Patient education (education group)
Number of subjects: 184
Study: 15295692

Group type: EXPERIMENTAL
Intervention: Phenotypic susceptibility score (PSS) weighted by inferred potency
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Entry VL
Number of subjects: 0
Study: 11351770

Group type: EXPERIMENTAL
Intervention: Sildenafil citrate
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 9827282

Group type: EXPERIMENTAL
Intervention: Azithromycin plus ethambutol
Number of subjects: 59

Group type: COMPARATOR
Intervention: Clarithromycin plus ethambutol
Number of subjects: 59
Study: 7603052

Group type: EXPERIMENTAL
Intervention: School-based AIDS prevention program (10-lesson classroom program in seventh grade with a 5-lesson booster in eighth grade)
Number of subjects: 312

Group type: COMPARATOR
Intervention: Basic AIDS education (current practice in their districts)
Number of subjects: 312

Group type: EXPERIMENTAL
Intervention: School-based AIDS prevention program
Number of subjects: 312
Study: 2104735

Group type: EXPERIMENTAL
Intervention: Inhaled ergotamine tartrate (1 puff, 0.36 mg)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 517990

Group type: EXPERIMENTAL
Intervention: Copper-releasing IUDs
Number of subjects: 0
Study: 30266044

Group type: EXPERIMENTAL
Intervention: Testimony regarding one piece of evidence
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Testimony regarding two pieces of independent evidence
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Testimony regarding two pieces of interdependent evidence
Number of subjects: 0
Study: 28603868

Group type: EXPERIMENTAL
Intervention: Pre-operative ultrasound-guided infraclavicular brachial plexus block
Number of subjects: 52

Group type: COMPARATOR
Intervention: Postoperative block with 0.5 ml.kg‐1 ropivacaine 0.75%
Number of subjects: 52
Study: 26014587

Group type: EXPERIMENTAL
Intervention: Transdermal donepezil patch 87.5 mg/25 cm(2) every 72 h
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Transdermal donepezil patch 175 mg/50 cm(2) every 72 h
Number of subjects: 0
Study: 23471752

Group type: EXPERIMENTAL
Intervention: New assessment form (experimental group)
Number of subjects: 8075

Group type: COMPARATOR
Intervention: Existing assessment form (control group)
Number of subjects: 8075
Study: 21716277

Group type: EXPERIMENTAL
Intervention: LBM415 at 1,000 mg b.i.d.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: LBM415 at 1,000 mg t.i.d.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: LBM415 at low doses (not specified)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: LBM415 at 1,000 mg single dose
Number of subjects: 0
Study: 19330359

Group type: EXPERIMENTAL
Intervention: Patient Neurotoxicity Questionnaire (PNQ)
Number of subjects: 300

Group type: COMPARATOR
Intervention: Physician assessments (National Cancer Institute Common Toxicity Criteria)
Number of subjects: 300
Study: 16436850

Group type: EXPERIMENTAL
Intervention: Local anesthetic
Number of subjects: 14

Group type: COMPARATOR
Intervention: Normal saline
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Ultrasound-guided technique
Number of subjects: 14
Study: 15296889

Group type: EXPERIMENTAL
Intervention: Tranexamic acid (TA) 1.5 g as a bolus, followed by a constant infusion of 200 mg/h until 1.5 g
Number of subjects: 46

Group type: COMPARATOR
Intervention: Placebo (0.9% saline)
Number of subjects: 46
Study: 11767232

Group type: EXPERIMENTAL
Intervention: Insulin lispro (LP)
Number of subjects: 148

Group type: COMPARATOR
Intervention: Human regular insulin (HR)
Number of subjects: 148
Study: 9237494

Group type: EXPERIMENTAL
Intervention: Fluvoxamine (100 mg)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 8001725

Group type: EXPERIMENTAL
Intervention: Salt (0.2 M and 0.4 M)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Salted formula (0.15 M)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Unsalted formula
Number of subjects: 0
Study: 3053601

Group type: EXPERIMENTAL
Intervention: Theolair‐SR
Number of subjects: 23

Group type: COMPARATOR
Intervention: Theo‐Dur
Number of subjects: 23
Study: 31916788

Group type: EXPERIMENTAL
Intervention: WE PLAY program (4-week online preschool teacher training)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Comparison group (no intervention)
Number of subjects: 6
Study: 31476615

Group type: EXPERIMENTAL
Intervention: Positive nonverbal behaviors directed by teachers toward one group
Number of subjects: 96

Group type: COMPARATOR
Intervention: Negative nonverbal behaviors directed by teachers toward another group
Number of subjects: 96
Study: 28303632

Group type: EXPERIMENTAL
Intervention: Bivalirudin monotherapy
Number of subjects: 4303

Group type: COMPARATOR
Intervention: UFH monotherapy
Number of subjects: 4303
Study: 25348274

Group type: EXPERIMENTAL
Intervention: Coronary revascularization
Number of subjects: 313

Group type: COMPARATOR
Intervention: Medical management in patients with impaired renal function
Number of subjects: 313
Study: 23772918

Group type: EXPERIMENTAL
Intervention: White participants in a condition with Black confederates being profiled (racial profiling condition)
Number of subjects: 0

Group type: COMPARATOR
Intervention: White participants in a White-profiling condition
Number of subjects: 0

Group type: COMPARATOR
Intervention: White participants in a no-profiling control condition
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Black participants across all three conditions (racial profiling, White-profiling, no-profiling)
Number of subjects: 0
Study: 21447471

Group type: EXPERIMENTAL
Intervention: Video iPods (educational technology intervention)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Control group (no technological intervention)
Number of subjects: 21
Study: 19786240

Group type: EXPERIMENTAL
Intervention: Aspirin and clopidogrel
Number of subjects: 50

Group type: COMPARATOR
Intervention: Aspirin and placebo
Number of subjects: 50
Study: 16684823

Group type: EXPERIMENTAL
Intervention: Metformin (425 mg/d) for 2 years
Number of subjects: 38

Group type: COMPARATOR
Intervention: Untreated
Number of subjects: 38
Study: 15277255

Group type: EXPERIMENTAL
Intervention: Doxorubicin 50 mg/m2 i.v. followed by paclitaxel 150 mg/m2 i.v. over 24 h plus filgrastim 5 microg/kg on days 3-12 (arm 2)
Number of subjects: 317

Group type: COMPARATOR
Intervention: Doxorubicin 60 mg/m2 i.v. followed by cisplatin 50 mg/m2 i.v. (arm 1)
Number of subjects: 317
Study: 11351769

Group type: EXPERIMENTAL
Intervention: Formoterol via Aerolizer inhaler (12 micrograms twice daily)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Formoterol via Turbuhaler inhaler (12 micrograms twice daily)
Number of subjects: 200
Study: 9236262

Group type: EXPERIMENTAL
Intervention: Ipriflavone (200 mg t.i.d.)
Number of subjects: 198

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 198
Study: 8237098

Group type: EXPERIMENTAL
Intervention: Nisoldipine 5 mg
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Nisoldipine 10 mg
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Nisoldipine 20 mg
Number of subjects: 16
Study: 3092363

Group type: EXPERIMENTAL
Intervention: Combination of all three interventions
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Triaging patients into various combinations of health education treatments
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Educational history as a triaging variable
Number of subjects: 0

Group type: COMPARATOR
Intervention: Randomized control group
Number of subjects: 0
Study: 29795295

Group type: EXPERIMENTAL
Intervention: 0.1% GRFT gel (HEC formulation)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Placebo gel (HEC formulation)
Number of subjects: 6
Study: 27180881

Group type: EXPERIMENTAL
Intervention: Arnebia euchroma ointment (AEO)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Silver sulfadiazine cream (SSD)
Number of subjects: 45
Study: 25148614

Group type: EXPERIMENTAL
Intervention: Le Fort I osteotomy
Number of subjects: 28

Group type: COMPARATOR
Intervention: Mandibular osteotomy (surgical control group)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Nonsurgical controls
Number of subjects: 28
Study: 22447888

Group type: EXPERIMENTAL
Intervention: Intracoronary abciximab
Number of subjects: 452

Group type: EXPERIMENTAL
Intervention: Manual aspiration thrombectomy
Number of subjects: 452
Study: 21455255

Group type: EXPERIMENTAL
Intervention: DOCp53 group (trans-tracheal Adp53 injection at 1 × 10(12) vp on day 1 and day 8, plus docetaxel at 75 mg/m² on day 2)
Number of subjects: 40

Group type: COMPARATOR
Intervention: DOC group (docetaxel at 75 mg/m² on day 1)
Number of subjects: 40
Study: 18639268

Group type: EXPERIMENTAL
Intervention: Lidocaine jelly instilled proximal to the stone before and after fragmentation
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control group (no lidocaine jelly)
Number of subjects: 50
Study: 16557619

Group type: EXPERIMENTAL
Intervention: Participants sentenced 16‐ and 17‐year‐old defendants similarly to 18‐ and 25‐year‐old defendants.
Number of subjects: 235

Group type: EXPERIMENTAL
Intervention: Perceived level of the defendant's responsibility.
Number of subjects: 235

Group type: EXPERIMENTAL
Intervention: General opinion about capital sentences.
Number of subjects: 235

Group type: EXPERIMENTAL
Intervention: Participants' comfort level with sentencing.
Number of subjects: 235
Study: 24944393

Group type: EXPERIMENTAL
Intervention: Manidipine 10 mg plus delapril 30 mg once daily for 12 weeks (Group 1)
Number of subjects: 312

Group type: EXPERIMENTAL
Intervention: Manidipine 10 mg plus delapril 30 mg once daily for 12 weeks (Group 2)
Number of subjects: 312
Study: 10903019

Group type: EXPERIMENTAL
Intervention: rHuEPO (600 U/kg s.c. on day 14 and if needed on day 7 before surgery)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: ANHD (implemented after induction of anaesthesia)
Number of subjects: 60

Group type: COMPARATOR
Intervention: PDAB (conventional PDAB up to 3 U starting 4 weeks before surgery)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: rHuEPO with moderate ANHD
Number of subjects: 60
Study: 8855179

Group type: EXPERIMENTAL
Intervention: Ciprofloxacin and a combination of amoxicillin and clavulanic acid for 3 days after hemorrhage (group 3)
Number of subjects: 119

Group type: COMPARATOR
Intervention: Control group (group 2)
Number of subjects: 119
Study: 1900488

Group type: EXPERIMENTAL
Intervention: Estrogen/progestin administration
Number of subjects: 0

Group type: COMPARATOR
Intervention: Gonadotropins
Number of subjects: 0
Study: 6621660

Group type: EXPERIMENTAL
Intervention: Tryptophan in 10 per cent glucose
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Valine in 5 per cent glucose
Number of subjects: 20

Group type: COMPARATOR
Intervention: Routine formula (Similac)
Number of subjects: 20
Study: 31987245

Group type: EXPERIMENTAL
Intervention: Isometric treatment
Number of subjects: 101

Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 101
Study: 30882238

Group type: EXPERIMENTAL
Intervention: Dapagliflozin
Number of subjects: 17160
Study: 28913611

Group type: EXPERIMENTAL
Intervention: Gadobutrol (GB)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Gadoterate (GT)
Number of subjects: 54
Study: 25307886

Group type: COMPARATOR
Intervention: Optilene LP mesh (OLP group)
Number of subjects: 145

Group type: EXPERIMENTAL
Intervention: Self-gripping Parietex ProGrip mesh (PPG group)
Number of subjects: 145
Study: 23881433

Group type: EXPERIMENTAL
Intervention: Fall training (12 training sessions, 60 min each, over 6 weeks)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 18
Study: 22166108

Group type: EXPERIMENTAL
Intervention: Cervitec Plus (C+)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Cervitec (C)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Placebo (P)
Number of subjects: 120
Study: 19307437

Group type: EXPERIMENTAL
Intervention: Compression, sclerotherapy, surgery, and endoluminal treatments
Number of subjects: 0
Study: 17584568

Group type: EXPERIMENTAL
Intervention: Primary PCI (group A, n = 36)
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Tenecteplase followed by PCI within 24 hours (group B, n = 30)
Number of subjects: 96

Group type: COMPARATOR
Intervention: Tenecteplase alone (group C, n = 30)
Number of subjects: 96
Study: 15493034

Group type: EXPERIMENTAL
Intervention: Diode laser irradiation (685 nm, 10 minutes, 30 mW)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Diode laser irradiation (830 nm, 5 minutes, 60 mW)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Antimycotic self-treatment with antifungal oral gel and antiseptic solution for dentures
Number of subjects: 70

Group type: COMPARATOR
Intervention: Placebo-sham irradiation
Number of subjects: 70
Study: 11518097

Group type: EXPERIMENTAL
Intervention: Instructions to remove finger when feeling heat
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Instructions to remove finger when feeling unpleasant
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Instructions to remove finger when feeling pain
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Instructions to remove finger when could no longer tolerate pain
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Higher stimulus intensities
Number of subjects: 10